We’ve recently updated our valuation analysis.

Capitol Health Valuation

Is CAJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAJ?

Other financial metrics that can be useful for relative valuation.

CAJ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA12.9x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does CAJ's PE Ratio compare to its peers?

The above table shows the PE ratio for CAJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.6x
IDX Integral Diagnostics
42.6x22.9%AU$622.0m
AHX Apiam Animal Health
26.7x17.4%AU$123.7m
ACL Australian Clinical Labs
3.9x-51.5%AU$690.8m
SLA SILK Laser Australia
17.3x21.0%AU$110.5m
CAJ Capitol Health
30.7x23.2%AU$329.5m

Price-To-Earnings vs Peers: CAJ is expensive based on its Price-To-Earnings Ratio (30.7x) compared to the peer average (22.6x).


Price to Earnings Ratio vs Industry

How does CAJ's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a5.0%
n/an/an/a

Price-To-Earnings vs Industry: CAJ is expensive based on its Price-To-Earnings Ratio (30.7x) compared to the Global Healthcare industry average (18.6x)


Price to Earnings Ratio vs Fair Ratio

What is CAJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAJ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.7x
Fair PE Ratio25.4x

Price-To-Earnings vs Fair Ratio: CAJ is expensive based on its Price-To-Earnings Ratio (30.7x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).


Share Price vs Fair Value

What is the Fair Price of CAJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAJ (A$0.31) is trading above our estimate of fair value (A$0.21)

Significantly Below Fair Value: CAJ is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.31
AU$0.39
+27.0%
11.2%AU$0.43AU$0.31n/a6
Nov ’23AU$0.33
AU$0.40
+21.8%
13.5%AU$0.48AU$0.31n/a6
Oct ’23AU$0.32
AU$0.41
+30.3%
13.6%AU$0.48AU$0.31n/a5
Sep ’23AU$0.32
AU$0.44
+38.3%
6.2%AU$0.48AU$0.42n/a4
Aug ’23AU$0.28
AU$0.41
+45.2%
11.1%AU$0.47AU$0.34n/a4
Jul ’23AU$0.29
AU$0.41
+40.3%
8.4%AU$0.47AU$0.37n/a4
Jun ’23AU$0.33
AU$0.42
+27.0%
7.0%AU$0.47AU$0.39n/a4
May ’23AU$0.33
AU$0.43
+32.7%
6.2%AU$0.47AU$0.40n/a5
Apr ’23AU$0.34
AU$0.43
+24.1%
5.4%AU$0.45AU$0.40n/a5
Mar ’23AU$0.36
AU$0.43
+17.3%
5.4%AU$0.45AU$0.40n/a5
Feb ’23AU$0.38
AU$0.42
+11.8%
10.6%AU$0.49AU$0.35n/a5
Jan ’23AU$0.39
AU$0.42
+8.7%
11.5%AU$0.49AU$0.35n/a4
Dec ’22AU$0.36
AU$0.42
+17.8%
11.5%AU$0.49AU$0.35n/a4
Nov ’22AU$0.34
AU$0.42
+24.2%
13.3%AU$0.49AU$0.35AU$0.333
Oct ’22AU$0.39
AU$0.42
+9.7%
13.3%AU$0.49AU$0.35AU$0.323
Sep ’22AU$0.36
AU$0.42
+17.8%
11.5%AU$0.49AU$0.35AU$0.324
Aug ’22AU$0.35
AU$0.37
+4.6%
12.3%AU$0.43AU$0.30AU$0.284
Jul ’22AU$0.38
AU$0.37
-1.0%
12.3%AU$0.43AU$0.30AU$0.294
Jun ’22AU$0.35
AU$0.37
+6.1%
12.3%AU$0.43AU$0.30AU$0.334
May ’22AU$0.38
AU$0.37
-1.0%
12.3%AU$0.43AU$0.30AU$0.334
Apr ’22AU$0.34
AU$0.37
+9.2%
12.3%AU$0.43AU$0.30AU$0.344
Mar ’22AU$0.34
AU$0.37
+7.6%
12.3%AU$0.43AU$0.30AU$0.364
Feb ’22AU$0.27
AU$0.31
+14.9%
8.8%AU$0.35AU$0.28AU$0.384
Jan ’22AU$0.28
AU$0.31
+12.8%
8.8%AU$0.35AU$0.28AU$0.394
Dec ’21AU$0.28
AU$0.31
+10.8%
8.8%AU$0.35AU$0.28AU$0.364
Nov ’21AU$0.25
AU$0.28
+11.9%
11.6%AU$0.31AU$0.23AU$0.344

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies